Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study

The Lancet ◽  
1999 ◽  
Vol 353 (9170) ◽  
pp. 2111-2115 ◽  
Author(s):  
Jayne A Franklyn ◽  
Patrick Maisonneuve ◽  
Michael Sheppard ◽  
Joan Betteridge ◽  
Peter Boyle
Gut ◽  
2020 ◽  
pp. gutjnl-2019-320200 ◽  
Author(s):  
Ru Chen ◽  
Yong Liu ◽  
Guohui Song ◽  
Bianyun Li ◽  
Deli Zhao ◽  
...  

ObjectivesTo estimate the effectiveness of endoscopic screening programme in reducing incidence and mortality of upper gastrointestinal cancer in high risks areas of China.DesignThis multicentre population-based cohort study was conducted in six areas in China from 2005 to 2015. All permanent residents aged 40 to 69 years were identified as target subjects. We refer to those who were invited for screening collectively as the invited group. Of these, we classify those who were invited and undertook endoscopic screening as the screened group and those who were invited but did not accept screening as the non-screened group. Target subjects who were not invited to the screening were assigned to the control group. The effectiveness of the endoscopic screening and screening programme were evaluated by comparing reductions in incidence and mortality from upper gastrointestinal cancer in the screened and invited group with control group.ResultsOur cohort analysis included 637 500 people: 299 483 in the control group and 338 017 in the invited to screening group, 113 340 (33.53%) of whom were screened eventually. Compared with subjects in the control group, upper gastrointestinal cancer incidence and mortality decreased by 23% (relative risk (RR)=0.77, 95% CI 0.74 to 0.81) and 57% (RR=0.43, 95% CI 0.40 to 0.47) in the screened group, respectively, and by 14% (RR=0.86, 95% CI 0.84 to 0.89) and 31% (RR=0.69, 95% CI 0.66 to 0.72) in the invited group, respectively.ConclusionAmong individuals aged 40 to 69 years in high risk areas of upper gastrointestinal cancer, one-time endoscopic screening programme was associated with a significant decrease in upper gastrointestinal cancer incidence and mortality.


2021 ◽  
Vol 96 (8) ◽  
pp. 2157-2167
Author(s):  
Casey R. Johnson ◽  
Daniel V. Dudenkov ◽  
Kristin C. Mara ◽  
Philip R. Fischer ◽  
Julie A. Maxson ◽  
...  

2019 ◽  
Vol 58 (6) ◽  
pp. 859-863 ◽  
Author(s):  
Salla Jäämaa-Holmberg ◽  
Birgitta Salmela ◽  
Karl Lemström ◽  
Eero Pukkala ◽  
Jyri Lommi

2020 ◽  
Vol 33 (Supplement_1) ◽  
Author(s):  
R Chen ◽  
Y Liu ◽  
G Song ◽  
B Li ◽  
D Zhao ◽  
...  

Abstract   Esophageal cancer is one of the most common cancers worldwide and half of all new cases occurred in China. Population-based endoscopic screening has been carried out in some high-risk areas in China since 2005, but previous evidence was based predominately on small-sample, single-center studies. We undertook a population-based, multi-center cohort study to estimate the effectiveness of endoscopic screening program in reducing the incidence and mortality of esophageal in high risks areas in China. Methods This study was conducted in six areas in China from 2005 to 2015. All permanent residents aged 40–69 yeas were identified as target subjects. We defined those who were invited and undertook endoscopic screening as the screened group, and those who refused screening as the non-screened group. The target subjects who were not invited to screening was assigned to the control group. The effectiveness of endoscopic screening and screening program were evaluated by comparing the reductions in the incidence and mortality from esophageal cancer in those screened or those invited to screening with reductions in the control group, respectively. Results Our cohort analysis included 637 500 people: 299 483 in the control group and 338 017 in the invited to screening group, 113 340 (33.53%) of whom were screened eventually. Compared with subjects in the control group, esophageal cancer incidence and mortality were reduced by 26% (relative risk(RR) 0.74, 95% confidence interval(CI), 0.69–0.79) and 60% (0.40, 0.36–0.45) respectively in those screened, and they were reduced by 15% (0.85, 0.82–0.89) and 33% (0.67, 0.63–0.71) respectively in those invited to screening. Conclusion Among individuals aged 40–69 years in high risk areas of esophageal cancer, one-time endoscopic screening program was associated with a significant decrease in esophageal cancer incidence and mortality.


Neurology ◽  
2020 ◽  
pp. 10.1212/WNL.0000000000011219
Author(s):  
Ruth Ann Marrie ◽  
Colleen Maxwell ◽  
Alyson Mahar ◽  
Okechukwu Ekuma ◽  
Chad McClintock ◽  
...  

Objective:To determine whether cancer risk differs in people with and without multiple sclerosis (MS), we compared incidence rates and cancer-specific mortality rates in MS and matched cohorts using population-based data sources.Methods:We conducted a retrospective matched cohort study using population-based administrative data from Manitoba and Ontario, Canada. We applied a validated case definition to identify MS cases, then selected 5 controls without MS matched on birth year, sex and region. We linked these cohorts to cancer registries, and estimated incidence of breast, colorectal and 13 other cancers. For breast and colorectal cancers, we constructed Cox models adjusting for age at the index date, area-level socioeconomic status, region, birth cohort year and comorbidity. We pooled findings across provinces using meta-analysis.Results:We included 53,984 MS cases and 266,920 controls. Multivariable analyses showed no difference in breast cancer risk (pooled hazard ratio [HR] 0.92 [95%CI: 0.78-1.09]) or colorectal cancer risk (pooled HR 0.83 [95%CI: 0.64-1.07]) between the cohorts. Mortality rates for breast and colorectal did not differ between cohorts. Bladder cancer incidence and mortality rates were higher among the MS cohort. Although the incidence of prostate, uterine and central nervous system cancers differed between the MS and matched cohorts, mortality rates did not.Conclusion:The incidence of breast and colorectal cancers does not differ between persons with and without MS; however, the incidence of bladder cancer is increased. Reported differences in the incidence of some cancers in the MS population may reflect ascertainment differences rather than true differences.


2021 ◽  
Vol 148 (12) ◽  
pp. 2982-2996
Author(s):  
Xiao‐Wei Ji ◽  
Jing Wang ◽  
Qiu‐Ming Shen ◽  
Zhuo‐Ying Li ◽  
Yu‐Fei Jiang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document